Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Operating Leases (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Operating Leases for 3 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases rose 162.44% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 million, a 162.44% increase, with the full-year FY2025 number at $2.5 million, up 162.44% from a year prior.
  • Operating Leases was $2.5 million for Q4 2025 at Nuvation Bio, down from $3.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $3.8 million in Q1 2025 to a low of $969000.0 in Q4 2024.
  • A 3-year average of $2.2 million and a median of $2.5 million in 2023 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: tumbled 61.36% in 2024, then skyrocketed 249.69% in 2025.
  • Nuvation Bio's Operating Leases stood at $2.0 million in 2023, then crashed by 52.38% to $969000.0 in 2024, then soared by 162.44% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Operating Leases are $2.5 million (Q4 2025), $3.0 million (Q3 2025), and $3.4 million (Q2 2025).